- Home
- NXE vs TFX Comparison
NXE vs TFX Comparison
Compare NXE & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXE | TFX |
|---|---|---|
| Founded | 2011 | 1943 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NXE | TFX |
|---|---|---|
| Price | $8.51 | $130.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $16.37 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 4.3M | 702.6K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.08 |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $13.82 |
| Revenue Next Year | N/A | $4.32 |
| P/E Ratio | ★ N/A | $62.69 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.33 | $100.18 |
| 52 Week High | $13.96 | $145.00 |
Technical Indicators
Market Signals| Indicator | NXE | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 57.54 |
| Support Level | N/A | $129.65 |
| Resistance Level | $9.66 | $137.48 |
| Average True Range (ATR) | 0.32 | 2.89 |
| MACD | -0.02 | 1.03 |
| Stochastic Oscillator | 31.25 | 88.82 |
Price Performance
Historical ComparisonAbout NXE Nexgen Energy Ltd.
NexGen Energy Ltd is an exploration and development stage entity engaged in the acquisition, exploration, evaluation, and development of uranium properties in Canada. The Rook I Project is a development-stage uranium project in Canada. The Company also holds a prospective portfolio of uranium exploration projects in the historic eastern Athabasca Basin.
About TFX Teleflex Incorporated
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.